Brief: Daewoong Pharmaceutical Announces Publication Of Novel P-Cab Fexuprazan Phase 1 Bridging Study
06/11/2020 14:19
Nov 6 (Reuters) - Daewoong Pharma 069620.KS :
* DAEWOONG PHARMACEUTICAL ANNOUNCES PUBLICATION OF NOVEL
P-CAB
FEXUPRAZAN PHASE 1 BRIDGING STUDY
Source text for Eikon: ID:nPre4TxWga
Further company coverage: 069620.KS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Daewoong Pharma
See all newsBrief: Daewoong Pharma Q2 Operating. Profit 77 Billion Won, Up 23% Y/Y
Brief: Daewoong Pharma Wins 92.6 Billion Won Order
Brief: Daewoong Pharma Q4 Operating Profit 45.5 Billion Won, Up 9% From Year Earlier
Brief: Daewoong Pharma Q2 Operating Profit 62.5 Billion Won, Up 26% From Year Earlier
Brief: Daewoong Pharma Q1 Operating Profit 42 Billion Won, Up 34.5% From Year Earlier